Breaking

China’s Xi stresses strength of Russia ties in Putin call as Washington warms to Moscow
Who was he? How did he get there? Wetsuit may hold key to mystery of body found in reservoir
France faces its largest child abuse trial, weeks after country was rocked by Pelicot case
Russia says it’s open to economic cooperation with US on rare earth minerals and energy
American teen arrested in Paris after newborn fatally thrown from hotel window, French media report
South Korea’s president is fighting to stay in office and out of prison after martial law fiasco. Here’s what happens next
Australia found out about Chinese navy live-fire drills through a commercial pilot, official says
Highway overpass collapses, killing at least four construction workers in South Korea

Business
World
Politics
Investing
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

Related Posts

Jindalee Realises $2.75M from Sale of Non-Core Asset

February 25, 2025

Virka Project Sampling Returns High-Grade Mineralisation

February 25, 2025

Craig Hemke: What’s Really Going on With Gold? Tariffs, Shortages, Fort Knox and More

February 25, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (1,272)
- Investing (2,738)
- Politics (3,833)
- World (3,755)

Disclaimer: RiskManagementMasters.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2024 RiskManagementMasters.com | All Rights Reserved

Top

Business
World
Politics
Investing

Type above and press Enter to search. Press Esc to cancel.